Nevertheless, the risk for developing hypertension also exceeds that of developing proteinuria in patients treated with different doses of the VEGF-antibody bevacizumab.[2], [36]In conclusion, the present results demonstrate that sFlt-1 augments ET-1 induced vasoconstriction, thereby contributing to BP elevation in mice. Here, VEGFA is linked to Hypertension.